Genmab announces EC marketing authorization for TIVDAK
Genmab (GMAB) announced that the European Commission has granted marketing authorization for TIVDAK, an antibody-drug conjugate, as monotherapy ...
Morningstar2d
TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer
TIVDAK® is the first and only antibody-drug conjugate (ADC) approved to treat recurrent or metastatic cervical cancer with disease progression on or after systemic therapy In the global Phase 3 ...
Genmab announces Tivdak approval in Japan
Genmab (GMAB) announced that the Japan Ministry of Health, Labour and Welfare has approved Tivdak for the treatment of advanced or recurrent ...
Insider Monkey2d
8 Most Undervalued Healthcare Stocks to Buy According to Analysts
It is developing ground-breaking medicines in oncology and other fields with a portfolio of commercialized medications that includes EPKINLY, TEPKINLY, and Tivdak, as well as a strong pipeline ...
Business Wire21d
Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer
TIVDAK, the only antibody-drug conjugate (ADC) therapy in cervical cancer, demonstrated promising benefits including a clinically meaningful improvement in overall survival (OS) in the pivotal ...
Yahoo Finance2d
TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer
“In clinical trials, TIVDAK demonstrated a superior overall survival benefit and manageable safety profile compared to chemotherapy, supporting its position to become a potential new standard of ...
TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer
Media Release COPENHAGEN, Denmark; March 31, 2025 TIVDAK® is the first and only antibody-drug conjugate (ADC) approved to treat recurrent or metastatic cervical cancer with disease progression on or ...